Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT05852262
PHASE4

High-dose Cephalexin for Cellulitis (HI-DOCC)

Sponsor: Ottawa Hospital Research Institute

View on ClinicalTrials.gov

Summary

Cellulitis is a common condition diagnosed and managed in the ED that carries significant burden on healthcare systems globally. Cellulitis is the 8th most common reason patients present to an ED in Canada. Among middle-aged patients (45-64 years) it is the 5th most common reason to visit an ED. This disease is responsible for significant healthcare system burden due to high hospitalization rates and subsequent costs. The Investigators conducted a health records review at two large urban EDs in Ottawa, and found that 29.6% of patients with cellulitis are admitted to hospital. In a separate study, The investigators found that the mean cost of care to hospitalize cellulitis patients for IV antibiotics was $10,145 CDN.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

446

Start Date

2023-08-30

Completion Date

2026-08-01

Last Updated

2025-10-01

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

Cephalexin

1000 mg PO QID for 7 days

DRUG

Cephalexin

500 mg PO QID plus oral placebo for 7 days

Locations (10)

South Health Campus

Calgary, Alberta, Canada

Queen Elisabeth II Health Sciences Centre

Halifax, Nova Scotia, Canada

Health Sciences North

Greater Sudbury, Ontario, Canada

Kingston Health Sciences Centre

Kingston, Ontario, Canada

London Health Sciences Centre

London, Ontario, Canada

The Ottawa Hospital

Ottawa, Ontario, Canada

Thunder Bay Health Sciences Centre

Thunder Bay, Ontario, Canada

Sinai Health System

Toronto, Ontario, Canada

Hôpital du Sacré-Cœur de Montréal

Montreal, Quebec, Canada

Enfant-Jésus Hospital

Québec, Quebec, Canada